Hoth Therapeutics, a subsidiary of Rocket One, has halted its Phase 2a trial of HT-001 early due to strong interim efficacy results in treating skin toxicity from cancer therapies. The company will seek FDA guidance to advance HT-001 into a potential Phase 3 trial, aiming to improve patient quality of life by managing side effects of EGFR inhibitor cancer treatments. This topical drug targets skin issues that often disrupt cancer therapy. Next steps depend on regulatory feedback and further data analysis.
HT-001's strong Phase 2a efficacy results are notable alongside Pluang's Health-sector snapshot. For readers following health stocks, here is Pluang's market snapshot as of Nov 03, 2026 20:11 WIB: Of 150 priced US Health-sector stocks, 75 rose and 69 fell. Vertex Pharmaceuticals (VRTX) traded at USD 565.98 with a 1-day change of +2.32% and a typical hold time of 123 days, with Pluang order activity showing 25% Sell and 75% Buy. Twist Bioscience (TWST) was priced at USD 131.82, up 2.15%, with a 27-day hold time and 18% Sell / 82% Buy activity. Amneal Pharmaceuticals (AMRX) closed at USD 20.00, down 2.15%, with a 12-day hold time and 0% Sell / 100% Buy activity.
The global Automatic FOUP Opener Market is projected to grow from USD 4.41 billion in 2026 to USD 6.04 billion by 2032, expanding at a CAGR of 5.36%. Growth is driven by increasing fab automation, stricter contamination control requirements, and dema...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
